| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-06-16 | Benlysta® (belimumab) | systemic lupus erythematosus (SLE) | 2 | GSK (UK) | Autoimmune diseases |
| 2017-06-16 | ADCT-301 | relapsed/refractory Non-Hodgkin or Hodgkin lymphoma | 1 | ADC Therapeutics (Switzerland) | Cancer - Oncology |
| 2017-06-16 | ADCT-402 | relapsed or refractory non-Hodgkin's lymphoma | 1 | ADC Therapeutics (Switzerland) | Cancer - Oncology |
| 2017-06-15 | OSE-127 (Effi-7) | ulcerative colitis | preclinical | OSE Immunotherapeutics (France) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2017-06-15 | Taltz® (ixekizumab) | active psoriatic arthritis | 3 | Eli Lilly (USA - IN) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-06-15 | GLS-5700 | Zika virus infection | 1 | Inovio Pharmaceuticals (USA - PA) | Infectious diseases |
| 2017-06-14 | pracinostat | myelodysplastic syndrome (MDS) | 2 | Mei Pharma (USA - CA) Helsinn Group (Switzerland) | Cancer - Oncology |
| 2017-06-14 | SNF472 - hexasodium phytate | calciphylaxis | 1 | Sanifit (Spain - Switzerland) | Rare diseases - Cardiovascular diseases |
| 2017-06-14 | [Zr-89]-HuMab-5B1 - MVT-2163 | locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies | 1 | MabVax Therapeutics (USA - CA) | Cancer - Oncology - Diagnostic |
| 2017-06-14 | sirukumab | rheumatoid arthritis | 3 | Janssen Research & Development, a J&J company (USA - NJ) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-06-14 | vobarilizumab (ALX-0061) | moderate to severe rheumatoid arthritis | 2b | Ablynx (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-06-14 | vobarilizumab (ALX-0061) | moderate to severe rheumatoid arthritis | 2b | Ablynx (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-06-14 | ARGX-110 | relapsed/refractory cutaneous T-cell lymphoma (CTCL) | 1b | Argen-X (Belgium - The Netherlands) | Cancer - Oncology |
| 2017-06-13 | Victoza® (liraglutide) | type 2 diabetes | Novo Nordisk (Denmark) | Metabolic diseases | |
| 2017-06-13 | Diamyd® | type 1 diabetes | 2 | Diamyd Medical (Sweden) | Autoimmune diseases - Metabolic diseases |
| 2017-06-13 | Cx601 (adipose derived allogeneic stem cell therapy) | complex perianal fistulas in patients with Crohn's disease | 3 | Tigenix (Belgium) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2017-06-12 | BIVV001 (also known as rFVIIIFc-VWF-XTEN) | hemophilia A | 1-2 | Bioverativ (USA - MA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-06-12 | dalantercept and axitinib | advanced renal cell carcinoma | 2 | Acceleron Pharma (USA - CA) | Cancer - Oncology |
| 2017-06-12 | cabozantinib and atezolizumab | locally advanced or metastatic urothelial carcinoma (UC), locally advanced or metastatic renal cell carcinoma | 1b | Exelixis (USA - CA) Roche (Switzerland) | Cancer - Oncology |
| 2017-06-12 | Jardiance® (empagliflozin) | chronic kidney disease | Boehringer Ingelheim (Germany) Eli Lilly (USA - IN) | Kidney diseases - Renal diseases |
